PLGA-based nanoparticles: An overview of biomedical applications
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hans, 2002, Biodegradable nanoparticles for drug delivery and targeting, Curr. Opin. Solid State Mater. Sci., 6, 319, 10.1016/S1359-0286(02)00117-1
Hillaireau, 2009, Nanocarriers' entry into the cell: relevance to drug delivery, Cell. Mol. Life Sci., 66, 2873, 10.1007/s00018-009-0053-z
Kumari, 2010, Biodegradable polymeric nanoparticles based drug delivery systems, Colloids Surf. B Biointerfaces, 75, 1, 10.1016/j.colsurfb.2009.09.001
Prokop, 2008, Nanovehicular intracellular delivery systems, J. Pharm. Sci., 97, 3518, 10.1002/jps.21270
Vert, 1994, Biodegradation of PLA/GA polymers: increasing complexity, Biomaterials, 15, 1209, 10.1016/0142-9612(94)90271-2
Vasir, 2007, Biodegradable nanoparticles for cytosolic delivery of therapeutics, Adv. Drug Deliv. Rev., 59, 718, 10.1016/j.addr.2007.06.003
Acharya, 2011, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect, Adv. Drug Deliv. Rev., 63, 170, 10.1016/j.addr.2010.10.008
Owens, 2006, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm., 307, 93, 10.1016/j.ijpharm.2005.10.010
Betancourt, 2009, PEGylation strategies for active targeting of PLA/PLGA nanoparticles, J. Biomed. Mater. Res., 91A, 263, 10.1002/jbm.a.32247
Foged, 2005, Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model, Int. J. Pharm., 298, 315, 10.1016/j.ijpharm.2005.03.035
Vasir, 2008, Quantification of the force of nanoparticle–cell membrane interactions and its influence on intracellular trafficking of nanoparticles, Biomaterials, 29, 4244, 10.1016/j.biomaterials.2008.07.020
Yue, 2011, Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles, Biomacromolecules, 12, 2440, 10.1021/bm101482r
Danhier, 2010, To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J. Control. Release, 148, 135, 10.1016/j.jconrel.2010.08.027
Tahara, 2009, Improved cellular uptake of chitosan-modified PLGA nanospheres by A549 cells, Int. J. Pharm., 382, 198, 10.1016/j.ijpharm.2009.07.023
Soppimath, 2001, Biodegradable polymeric nanoparticles as drug delivery devices, J. Control. Release, 70, 1, 10.1016/S0168-3659(00)00339-4
Fessi, 1989, Nanocapsule formation by interfacial polymer deposition following solvent displacement, Int. J. Pharm., 55, R1, 10.1016/0378-5173(89)90281-0
Gaumet, 2008, Nanoparticles for drug delivery: the need for precision in reporting particle size parameters, Eur. J. Pharm. Biopharm., 69, 1, 10.1016/j.ejpb.2007.08.001
Fonseca, 2002, Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity, J. Control. Release, 83, 273, 10.1016/S0168-3659(02)00212-2
Derakhshandeh, 2007, Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics, Eur. J. Pharm. Biopharm., 66, 34, 10.1016/j.ejpb.2006.09.004
Avgoustakis, 2002, PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties, J. Control. Release, 79, 123, 10.1016/S0168-3659(01)00530-2
Budhian, 2005, Production of haloperidol-loaded PLGA nanoparticles for extended controlled drug release of haloperidol, J. Microencapsul., 22, 773, 10.1080/02652040500273753
Mittal, 2007, Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo, J. Control. Release, 119, 77, 10.1016/j.jconrel.2007.01.016
Talmadge, 1993, The pharmaceutics and delivery of therapeutic polypeptides and proteins, Adv. Drug Deliv. Rev., 10, 247, 10.1016/0169-409X(93)90049-A
van de Weert, 2000, Protein instability in poly(lactic-co-glycolic acid) microparticles, Pharm. Res., 17, 1159, 10.1023/A:1026498209874
Giteau, 2008, Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres, Eur. J. Pharm. Biopharm., 70, 127, 10.1016/j.ejpb.2008.03.006
Cleland, 1993, The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation, Crit. Rev. Ther. Drug Carrier Syst., 10, 307
Zhu, 2000, Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide), Nat. Biotechnol., 18, 52, 10.1038/71916
Kumar, 2006, Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles, Pharmazie, 61, 613
Kumar, 2007, Novel approach for delivery of insulin loaded poly(lactide-co-glycolide) nanoparticles using a combination of stabilizers, Drug Deliv., 14, 517, 10.1080/10717540701606467
Ribeiro, 2005, Release of DNA from dendriplexes encapsulated in PLGA nanoparticles, Int. J. Pharm., 298, 354, 10.1016/j.ijpharm.2005.03.036
Kim, 2005, Physicochemical characterization of poly(l-lactic acid) and poly(d,l-lactide-co-glycolide) nanoparticles with polyethylenimine as gene delivery carrier, Int. J. Pharm., 298, 255, 10.1016/j.ijpharm.2005.04.017
Davda, 2002, Characterization of nanoparticle uptake by endothelial cells, Int. J. Pharm., 233, 51, 10.1016/S0378-5173(01)00923-1
Niu, 2009, Modified nanoprecipitation method to fabricate DNA-loaded PLGA nanoparticles, Drug Dev. Ind. Pharm., 35, 1375, 10.3109/03639040902939221
Prabha, 2004, Critical determinants in PLGA/PLA nanoparticle-mediated gene expression, Pharm. Res., 21, 354, 10.1023/B:PHAM.0000016250.56402.99
Sun, 2011, Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3, Oncol. Rep., 26, 193
Tahara, 2008, Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery, Int. J. Pharm., 354, 210, 10.1016/j.ijpharm.2007.11.002
Patil, 2010, The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance, Biomaterials, 31, 358, 10.1016/j.biomaterials.2009.09.048
Cun, 2011, High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization, Eur. J. Pharm. Biopharm., 77, 26, 10.1016/j.ejpb.2010.11.008
Beaudette, 2009, In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in acid-degradable microparticle vaccines, Mol. Pharm., 6, 1160, 10.1021/mp900038e
de Jong, 2007, Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN, Cancer Immunol. Immunother., 56, 1251, 10.1007/s00262-006-0276-x
Clawson, 2010, Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity, Nanomedicine, 6, 651, 10.1016/j.nano.2010.03.001
Diwan, 2003, Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses, J. Drug Target., 11, 495, 10.1080/10611860410001670026
Prasad, 2011, Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy, Nanomedicine, 7, 1, 10.1016/j.nano.2010.07.002
Solbrig, 2007, Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells, Mol. Pharm., 4, 47, 10.1021/mp060107e
Thomas, 2010, Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine, Mol. Pharm., 8, 405, 10.1021/mp100255c
Tian, 2011, Poly(lactic-co-glycolic acid) nanoparticles as candidate DNA vaccine carrier for oral immunization of Japanese flounder (Paralichthys olivaceus) against lymphocystis disease virus, Fish Shellfish Immunol., 30, 109, 10.1016/j.fsi.2010.09.016
Jiang, 2005, Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens, Adv. Drug Deliv. Rev., 57, 391, 10.1016/j.addr.2004.09.003
Slutter, 2010, Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen, Vaccine, 28, 6282, 10.1016/j.vaccine.2010.06.121
Brunner, 2010, The ABC of clinical and experimental adjuvants—a brief overview, Immunol. Lett., 128, 29, 10.1016/j.imlet.2009.10.005
Diwan, 2004, Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery, Curr. Drug Deliv., 1, 405, 10.2174/1567201043334597
Elamanchili, 2007, “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells, J. Immunother., 30, 378, 10.1097/CJI.0b013e31802cf3e3
Hamdy, 2008, Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity, Vaccine, 26, 5046, 10.1016/j.vaccine.2008.07.035
Arens, 2010, Plasticity in programming of effector and memory CD8 T-cell formation, Immunol. Rev., 235, 190, 10.1111/j.0105-2896.2010.00899.x
Shen, 2006, Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles, Immunology, 117, 78, 10.1111/j.1365-2567.2005.02268.x
Alexis, 2008, Factors affecting the clearance and biodistribution of polymeric nanoparticles, Mol. Pharm., 5, 505, 10.1021/mp800051m
Kelly, 2011, Targeted liposomal drug delivery to monocytes and macrophages, J. Drug Deliv., 2011, 727241, 10.1155/2011/727241
Jain, 2000, The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices, Biomaterials, 21, 2475, 10.1016/S0142-9612(00)00115-0
Bachmann, 2010, Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns, Nat. Rev. Immunol., 10, 787, 10.1038/nri2868
Cho, 2008, Therapeutic nanoparticles for drug delivery in cancer, Clin. Cancer Res., 14, 1310, 10.1158/1078-0432.CCR-07-1441
Manolova, 2008, Nanoparticles target distinct dendritic cell populations according to their size, Eur. J. Immunol., 38, 1404, 10.1002/eji.200737984
Rao, 2010, Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials, Am. J. Clin. Pathol., 133, 646, 10.1309/AJCPTXMEFOVYWDA6
Burgdorf, 2008, Endocytosis mechanisms and the cell biology of antigen presentation, Curr. Opin. Immunol., 20, 89, 10.1016/j.coi.2007.12.002
Fernandez-Megia, 2007, Conjugation of bioactive ligands to PEG-grafted chitosan at the distal end of PEG, Biomacromolecules, 8, 833, 10.1021/bm060889x
van den Berg, 2010, Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity, J. Control. Release, 141, 234, 10.1016/j.jconrel.2009.09.005
Kadowaki, 2007, Dendritic cells: a conductor of T cell differentiation, Allergol. Int., 56, 193, 10.2332/allergolint.R-07-146
Kumar, 2009, Pathogen recognition in the innate immune response, Biochem. J., 420, 1, 10.1042/BJ20090272
Takeuchi, 2010, Pattern recognition receptors and inflammation, Cell, 140, 805, 10.1016/j.cell.2010.01.022
Bekeredjian-Ding, 2009, Toll-like receptors—sentries in the B-cell response, Immunology, 128, 311, 10.1111/j.1365-2567.2009.03173.x
Liu, 2010, Modulation of immune responses through direct activation of Toll-like receptors to T cells, Clin. Exp. Immunol., 160, 168, 10.1111/j.1365-2249.2010.04091.x
Gazi, 2009, Influence of the mannose receptor in host immune responses, Immunobiology, 214, 554, 10.1016/j.imbio.2008.11.004
Hamdy, 2011, Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles, Pharm. Res., 9, 2288, 10.1007/s11095-011-0459-9
Joshi, 2011, DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations, Int. J. Pharm., 2, 426, 10.1016/j.ijpharm.2011.02.055
Cruz, 2010, Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro, J. Control. Release, 144, 118, 10.1016/j.jconrel.2010.02.013
O'Reilly, 2009, Siglecs as targets for therapy in immune-cell-mediated disease, Trends Pharmacol. Sci., 30, 240, 10.1016/j.tips.2009.02.005
von, 2008, Basic and clinical immunology of Siglecs, Ann. N. Y. Acad. Sci., 1143, 61, 10.1196/annals.1443.011
Jandus, 2011, Targeting Siglecs—a novel pharmacological strategy for immuno- and glycotherapy, Biochem. Pharmacol., 82, 323, 10.1016/j.bcp.2011.05.018
Scott, 2008, Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-co-glycolide) nanoparticles, Pharm. Res., 25, 135, 10.1007/s11095-007-9400-7
des Rieux, 2006, Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach, J. Control. Release, 116, 1, 10.1016/j.jconrel.2006.08.013
Rajapaksa, 2010, Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery, J. Control. Release, 142, 196, 10.1016/j.jconrel.2009.10.033
Garinot, 2007, PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination, J. Control. Release, 120, 195, 10.1016/j.jconrel.2007.04.021
Fievez, 2009, Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination, Eur. J. Pharm. Biopharm., 73, 16, 10.1016/j.ejpb.2009.04.009
Fernandez, 2012, Activation of invariant Natural Killer T lymphocytes in response to the [alpha]-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles, Int. J. Pharm., 423, 45, 10.1016/j.ijpharm.2011.04.068
Zhang, 2011, Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery, Biomaterials, 32, 3666, 10.1016/j.biomaterials.2011.01.067
Hanlon, 2011, Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen, Am. J. Reprod. Immunol., 65, 597, 10.1111/j.1600-0897.2010.00968.x
Yaguchi, 2011, The mechanisms of cancer immunoescape and development of overcoming strategies, Int. J. Hematol., 93, 294, 10.1007/s12185-011-0799-6
Molavi, 2010, Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy, Mol. Pharm., 7, 364, 10.1021/mp900145g
Molavi, 2009, Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124, Immunopharmacol. Immunotoxicol., 31, 214, 10.1080/08923970802380452
Alshamsan, 2011, STAT3 knockdown in B16 melanoma by siRNA lipopolyplexes induces bystander immune response in vitro and in vivo, Transl. Oncol., 4, 178, 10.1593/tlo.11100
Roy, 2010, Combined chemo-immunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach, Mol. Pharm., 7, 1778, 10.1021/mp100153r
Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 46, 6387
Folkman, 1971, Tumor angiogenesis: therapeutic implications, N. Engl. J. Med., 285, 1182, 10.1056/NEJM197111182852108
Kirpotin, 2006, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models, Cancer Res., 66, 6732, 10.1158/0008-5472.CAN-05-4199
Park, 2009, PEGylated PLGA nanoparticles for the improved delivery of doxorubicin, Nanomedicine, 5, 410, 10.1016/j.nano.2009.02.002
Wohlfart, 2011, Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers, PLoS One, 6, e19121, 10.1371/journal.pone.0019121
Danhier, 2009, Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation, J. Control. Release, 133, 11, 10.1016/j.jconrel.2008.09.086
Chittasupho, 2009, ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells, Eur. J. Pharm. Sci., 37, 141, 10.1016/j.ejps.2009.02.008
Zhang, 2007, Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery, Biomaterials, 28, 1889, 10.1016/j.biomaterials.2006.12.018
Liang, 2011, Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma, Bioorg. Med. Chem., 19, 4057, 10.1016/j.bmc.2011.05.016
Luo, 2010, LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors, Int. J. Pharm., 385, 150, 10.1016/j.ijpharm.2009.10.014
Dhar, 2008, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles, Proc. Natl. Acad. Sci. U. S. A., 105, 17356, 10.1073/pnas.0809154105
Guo, 2011, Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery, Biomaterials, 31, 8010, 10.1016/j.biomaterials.2011.07.004
Desgrosellier, 2010, Integrins in cancer: biological implications and therapeutic opportunities, Nat. Rev. Cancer, 10, 9, 10.1038/nrc2748
Wang, 2009, Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells, Pharm. Res., 26, 1162, 10.1007/s11095-009-9837-y
Danhier, 2009, Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with paclitaxel, J. Control. Release, 140, 166, 10.1016/j.jconrel.2009.08.011
Zhao, 2010, Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies, J. Pharm. Sci., 99, 3552, 10.1002/jps.22113
Jain, 2011, The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen, Biomaterials, 32, 503, 10.1016/j.biomaterials.2010.09.037
Toti, 2011, Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles, Biomaterials, 32, 6606, 10.1016/j.biomaterials.2011.05.038
Choi, 2006, G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method, Int. J. Pharm., 311, 223, 10.1016/j.ijpharm.2005.12.023
Chen, 2008, Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy, J. Control. Release, 128, 209, 10.1016/j.jconrel.2008.03.010
Luo, 2009, RNA interference of MBD1 in BxPC-3 human pancreatic cancer cells delivered by PLGA-poloxamer nanoparticles, Cancer Biol. Ther., 8, 594, 10.4161/cbt.8.7.7790
Andersen, 2010, Surface functionalisation of PLGA nanoparticles for gene silencing, Biomaterials, 31, 5671, 10.1016/j.biomaterials.2010.03.069
Diez, 2009, Targeted cationic poly(d,l-lactic-co-glycolic acid) nanoparticles for gene delivery to cultured cells, Cell Mol. Biol. Lett., 14, 347, 10.2478/s11658-009-0003-7
Braden, 2009, Polymeric nanoparticles for sustained down-regulation of annexin A2 inhibit prostate tumor growth, J. Nanosci. Nanotechnol., 9, 2856, 10.1166/jnn.2009.028
Rangel, 2003, Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas, Clin. Cancer Res., 9, 2567
Sharma, 2011, Nanoparticle-mediated p53 gene therapy for tumor inhibition, Drug Deliv. Transl. Res., 1, 43, 10.1007/s13346-010-0008-9
Wang, 2008, Formulation of superparamagnetic iron oxides by nanoparticles of biodegradable polymers for magnetic resonance imaging, Adv. Funct. Mater., 18, 308, 10.1002/adfm.200700456
Janib, 2010, Imaging and drug delivery using theranostic nanoparticles, Adv. Drug Deliv. Rev., 62, 1052, 10.1016/j.addr.2010.08.004
Lubbe, 1996, Preclinical experiences with magnetic drug targeting: tolerance and efficacy, Cancer Res., 56, 4694
Lubbe, 1996, Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors, Cancer Res., 56, 4686
Singh, 2011, Composite polymeric magnetic nanoparticles for co-delivery of hydrophobic and hydrophilic anticancer drugs and MRI imaging for cancer therapy, ACS Appl. Mater. Interfaces, 3, 842, 10.1021/am101196v
Gref, 1994, Biodegradable long-circulating polymeric nanospheres, Science, 263, 1600, 10.1126/science.8128245
Ulbrich, 2010, Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases, J. R. Soc. Interface, 7, S55, 10.1098/rsif.2009.0285.focus
Simone, 2009, Targeted delivery of therapeutics to endothelium, Cell Tissue Res., 335, 283, 10.1007/s00441-008-0676-7
Meissner, 2008, Alternative drug delivery approaches for the therapy of inflammatory bowel disease, J. Pharm. Sci., 97, 2878, 10.1002/jps.21216
Lamprecht, 2001, Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa, Pharm. Res., 18, 788, 10.1023/A:1011032328064
Schmidt, 2010, W1266 confocal laser endomicroscopy (CLE) reveals mucosal accumulation of PLGA-nanoparticles in ulcerous lesions of patients with inflammatory bowel diseases, Gastroenterology, 138, S-687, 10.1016/S0016-5085(10)63157-5
Lamprecht, 2001, Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease, J. Pharmacol. Exp. Ther., 299, 775
Lamprecht, 2005, Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats, J. Pharmacol. Exp. Ther., 315, 196, 10.1124/jpet.105.088146
Meissner, 2006, Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery, Int. J. Pharm., 316, 138, 10.1016/j.ijpharm.2006.01.032
Lee, 2003, Pharmacological treatment of established rheumatoid arthritis, Best Pract. Res. Clin. Rheumatol., 17, 811, 10.1016/S1521-6942(03)00048-2
Horisawa, 2002, Size-dependency of dl-lactide/glycolide copolymer particulates for intra-articular delivery system on phagocytosis in rat synovium, Pharm. Res., 19, 132, 10.1023/A:1014260513728
Higaki, 2005, Treatment of experimental arthritis with poly(d,l-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate, Ann. Rheum. Dis., 64, 1132, 10.1136/ard.2004.030759
Horisawa, 2002, Prolonged anti-inflammatory action of dl-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit, Pharm. Res., 19, 403, 10.1023/A:1015123024113
Vij, 2010, Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis, J. Nanobiotechnol., 8, 22, 10.1186/1477-3155-8-22
Cartiera, 2010, Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin, Mol. Pharm., 7, 86, 10.1021/mp900138a
Zhang, 2004, Model of transient drug diffusion across cornea, J. Control. Release, 99, 241, 10.1016/j.jconrel.2004.07.001
Guinedi, 2005, Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide, Int. J. Pharm., 306, 71, 10.1016/j.ijpharm.2005.09.023
Kohane, 2006, Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum, J. Biomed. Mater. Res. A, 77, 351, 10.1002/jbm.a.30654
Patravale, 2004, Nanosuspensions: a promising drug delivery strategy, J. Pharm. Pharmacol., 56, 827, 10.1211/0022357023691
Schalnus, 2003, Topical nonsteroidal anti-inflammatory therapy in ophthalmology, Ophthalmologica, 217, 89, 10.1159/000068563
Agnihotri, 2009, Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application, Nanomedicine, 5, 90, 10.1016/j.nano.2008.07.003
Araujo, 2009, Effect of polymer viscosity on physicochemical properties and ocular tolerance of FB-loaded PLGA nanospheres, Colloids Surf. B Biointerfaces, 72, 48, 10.1016/j.colsurfb.2009.03.028
Vega, 2008, PLGA nanospheres for the ocular delivery of flurbiprofen: drug release and interactions, J. Pharm. Sci., 97, 5306, 10.1002/jps.21383
Dillen, 2006, Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles, Int. J. Pharm., 314, 72, 10.1016/j.ijpharm.2006.01.041
Costantino, 2006, Nanoparticulate drug carriers based on hybrid poly(d,l-lactide-co-glycolide)-dendron structures, Biomaterials, 27, 4635, 10.1016/j.biomaterials.2006.04.026
Reddy, 2008, Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress, Appl. Biochem. Biotechnol., 151, 565, 10.1007/s12010-008-8232-1
Reddy, 2009, Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury, FASEB J., 23, 1384, 10.1096/fj.08-116947
Hu, 2009, Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations, J. Control. Release, 134, 55, 10.1016/j.jconrel.2008.10.016
Hu, 2011, Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease, Int. J. Pharm., 415, 273, 10.1016/j.ijpharm.2011.05.062
Tosi, 2007, Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123, J. Control. Release, 122, 1, 10.1016/j.jconrel.2007.05.022
Costantino, 2005, Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier, J. Control. Release, 108, 84, 10.1016/j.jconrel.2005.07.013
Bondioli, 2010, PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid, Biomaterials, 31, 3395, 10.1016/j.biomaterials.2010.01.049
Tosi, 2010, Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: in vivo pharmacological evidence and biodistribution, J. Control. Release, 145, 49, 10.1016/j.jconrel.2010.03.008
Li, 2011, Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides, Biomaterials, 32, 4943, 10.1016/j.biomaterials.2011.03.031
Ladewig, 2011, Drug delivery in soft tissue engineering, Expert. Opin. Drug Deliv., 9, 1175, 10.1517/17425247.2011.588698
Wang, 2008, Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury, Biomaterials, 29, 4546, 10.1016/j.biomaterials.2008.07.050
Kordower, 1999, Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease, Ann. Neurol., 46, 419, 10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q
Nutt, 2003, Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD, Neurology, 60, 69, 10.1212/WNL.60.1.69
Gill, 2003, Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease, Nat. Med., 9, 589, 10.1038/nm850
Patel, 2005, Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study, Ann. Neurol., 57, 298, 10.1002/ana.20374
Slevin, 2005, Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor, J. Neurosurg., 102, 216, 10.3171/jns.2005.102.2.0216
Lang, 2006, Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease, Ann. Neurol., 59, 459, 10.1002/ana.20737
Garbayo, 2009, Effective GDNF brain delivery using microspheres—a promising strategy for Parkinson's disease, J. Control. Release, 135, 119, 10.1016/j.jconrel.2008.12.010
Garbayo, 2011, Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of parkinson's disease, Mov. Disord., 10, 1943, 10.1002/mds.23793
Jollivet, 2004, Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease, Biomaterials, 25, 933, 10.1016/S0142-9612(03)00601-X
Cao, 2004, Olfactory ensheathing cells genetically modified to secrete GDNF to promote spinal cord repair, Brain, 127, 535, 10.1093/brain/awh072
Cheng, 2002, Neuroprotection of glial cell line-derived neurotrophic factor in damaged spinal cords following contusive injury, J. Neurosci. Res., 69, 397, 10.1002/jnr.10303
Foust, 2008, Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat, Hum. Gene Ther., 19, 71, 10.1089/hum.2007.104
Tai, 2003, Gene transfer of glial cell line-derived neurotrophic factor promotes functional recovery following spinal cord contusion, Exp. Neurol., 183, 508, 10.1016/S0014-4886(03)00130-4
des Rieux, 2011, 3D systems delivering VEGF to promote angiogenesis for tissue engineering, J. Control. Release, 150, 272, 10.1016/j.jconrel.2010.11.028
Carmeliet, 2011, Molecular mechanisms and clinical applications of angiogenesis, Nature, 473, 298, 10.1038/nature10144
Ruiz de, 2009, Role and therapeutic potential of VEGF in the nervous system, Physiol. Rev., 89, 607, 10.1152/physrev.00031.2008
Panyam, 2003, Biodegradable nanoparticles for drug and gene delivery to cells and tissue, Adv. Drug Deliv. Rev., 55, 329, 10.1016/S0169-409X(02)00228-4
Golub, 2010, Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth, Am. J. Physiol. Heart Circ. Physiol., 298, H1959, 10.1152/ajpheart.00199.2009
Geng, 2011, Sustained release of VEGF from PLGA nanoparticles embedded thermo-sensitive hydrogel in full-thickness porcine bladder acellular matrix, Nanoscale Res. Lett., 6, 312, 10.1186/1556-276X-6-312
Chappell, 2008, Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis, Small, 4, 1769, 10.1002/smll.200800806
Lee, 2000, VEGF gene delivery to myocardium: deleterious effects of unregulated expression, Circulation, 102, 898, 10.1161/01.CIR.102.8.898
Price, 1998, Delivery of colloidal particles and red blood cells to tissue through microvessel ruptures created by targeted microbubble destruction with ultrasound, Circulation, 98, 1264, 10.1161/01.CIR.98.13.1264
Song, 2002, Influence of injection site, microvascular pressureand ultrasound variables on microbubble-mediated delivery of microspheres to muscle, J. Am. Coll. Cardiol., 39, 726, 10.1016/S0735-1097(01)01793-4
Bessa, 2008, Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts), J. Tissue Eng. Regen. Med., 2, 1, 10.1002/term.63
McKay, 2007, A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft), Int. Orthop., 31, 729, 10.1007/s00264-007-0418-6
White, 2007, Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion, Int. Orthop., 31, 735, 10.1007/s00264-007-0422-x
Cho, 2002, Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing, J. Bone Miner. Res., 17, 513, 10.1359/jbmr.2002.17.3.513
Yilgor, 2010, Sequential BMP-2/BMP-7 delivery from polyester nanocapsules, J. Biomed. Mater. Res., 93A, 528, 10.1002/jbm.a.32520
Yilgor, 2009, Incorporation of a sequential BMP-2/BMP-7 delivery system into chitosan-based scaffolds for bone tissue engineering, Biomaterials, 30, 3551, 10.1016/j.biomaterials.2009.03.024
Yilgor, 2010, Effect of scaffold architecture and BMP-2/BMP-7 delivery on in vitro bone regeneration, J. Mater. Sci. Mater. Med., 21, 2999, 10.1007/s10856-010-4150-1
Klugherz, 2000, Gene delivery from a DNA controlled-release stent in porcine coronary arteries, Nat. Biotechnol., 18, 1181, 10.1038/81176
Perlstein, 2003, DNA delivery from an intravascular stent with a denatured collagen-polylactic-polyglycolic acid-controlled release coating: mechanisms of enhanced transfection, Gene Ther., 10, 1420, 10.1038/sj.gt.3302043
Kannan, 2005, Current status of prosthetic bypass grafts: a review, J. Biomed. Mater. Res. B Appl. Biomater., 74, 570, 10.1002/jbm.b.30247
Sarkar, 2006, Development and characterization of a porous micro-patterned scaffold for vascular tissue engineering applications, Biomaterials, 27, 4775, 10.1016/j.biomaterials.2006.04.038
Lim, 2007, A novel technique for loading of paclitaxel-PLGA nanoparticles onto ePTFE vascular grafts, Biotechnol. Prog., 23, 693, 10.1021/bp060338i
Lecaroz, 2006, Nanocarriers with gentamicin to treat intracellular pathogens, J. Nanosci. Nanotechnol., 6, 3296, 10.1166/jnn.2006.478
Lecaroz, 2007, Poly(d,l-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice, Antimicrob. Agents Chemother., 51, 1185, 10.1128/AAC.00809-06
Imbuluzqueta, 2011, Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections, Acta Biomater., 7, 1599, 10.1016/j.actbio.2010.11.031
Pillai, 2008, Nafcillin-loaded PLGA nanoparticles for treatment of osteomyelitis, Biomed. Mater., 3, 034114, 10.1088/1748-6041/3/3/034114
Gupta, 2010, Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery, Nanomedicine, 6, 324, 10.1016/j.nano.2009.10.004
McDermott, 1987, The role of calcitonin in the development and treatment of osteoporosis, Endocr. Rev., 8, 377, 10.1210/edrv-8-4-377
Jung, 2009, Enhanced oral absorption of salmon calcitonin-encapsulated PLGA nanoparticles by adding organic substances, Korean J. Chem. Eng., 26, 131, 10.1007/s11814-009-0020-2
Yamamoto, 2005, Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions, J. Control. Release, 102, 373, 10.1016/j.jconrel.2004.10.010
Cui, 2007, Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery, J. Pharm. Sci., 96, 421, 10.1002/jps.20750
Shi, 2008, Optimized preparation of insulin-lauryl sulfate complex loaded poly (lactide-co-glycolide) nanoparticles using response surface methodology, Pharmazie, 63, 721
Shi, 2008, Investigation of drug loading and in vitro release mechanisms of insulin-lauryl sulfate complex loaded PLGA nanoparticles, Pharmazie, 63, 866
Shi, 2009, Optimized formulation of high-payload PLGA nanoparticles containing insulin-lauryl sulfate complex, Drug Dev. Ind. Pharm., 35, 177, 10.1080/03639040802235894
Sun, 2010, Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation, J. Microencapsul., 27, 471, 10.3109/02652040903515490
Cui, 2006, Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation, J. Control. Release, 114, 242, 10.1016/j.jconrel.2006.05.013